PT - JOURNAL ARTICLE AU - Giesel, Frederik L. AU - Will, Leon AU - Kesch, Claudia AU - Freitag, Martin AU - Kremer, Christophe AU - Merkle, Jonas AU - Neels, Oliver C. AU - Cardinale, Jens AU - Hadaschik, Boris AU - Hohenfellner, Markus AU - Kopka, Klaus AU - Haberkorn, Uwe AU - Kratochwil, Clemens TI - Biochemical Recurrence of Prostate Cancer: Initial Results with [<sup>18</sup>F]PSMA-1007 PET/CT AID - 10.2967/jnumed.117.196329 DP - 2018 Apr 01 TA - Journal of Nuclear Medicine PG - 632--635 VI - 59 IP - 4 4099 - http://jnm.snmjournals.org/content/59/4/632.short 4100 - http://jnm.snmjournals.org/content/59/4/632.full SO - J Nucl Med2018 Apr 01; 59 AB - Biochemical recurrence (BCR) is a concern for prostate cancer patients after local treatment. 68Ga-labeled prostate-specific membrane antigen (PSMA) ligands have significantly improved prostate cancer imaging. However, several 18F-labeled ligands that were developed as fluorinated tracers might present advantages. In this study, we analyzed the potential of 18F-PSMA-1007 in patients with BCR. Methods: Twelve patients with BCR after local treatment underwent PET/CT scans 1 and 3 h after injection of 18F-PSMA-1007. Results: 18F-PSMA-1007 PET/CT detected lesions in 9 of 12 patients (75%). A significant difference was observed when comparing the tracer uptake in 18F-PSMA-1007–positive lesions 1 and 3 h after injection (median SUVmax, 7.00 vs. 11.34; P &lt; 0.001; n = 76). Forty-four (88%) of 50 18F-PSMA-1007–positive lymph nodes had a short-axis diameter of less than 8 mm. Conclusion: In this pilot study, 18F-PSMA-1007 PET/CT presented high potential for localization of recurrent disease in prostate cancer patients with BCR.